Reviewed by Michael Gill, B. Sc.
3 Movantik Clinical Trials Near Me
Top Cities for Movantik Clinical Trials
Image of Columbia in Missouri.
Columbia
1Active Trials
Kara B. GoddardTop Active Site
Image of Cincinnati in Ohio.
Cincinnati
1Active Trials
Bethesda North TriHealth HospitalTop Active Site
Movantik Clinical Trials by Phase of Trial
Phase 2 & 3 Movantik Clinical Trials
1Active Movantik Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
Most Recent Movantik Clinical Trials
Clinical Trial
Began Recruiting Date
Phase

What Are Movantik Clinical Trials?

Movantik clinical trials might be most vividly described to fans of the cult classic movie Trainspotting. Remember that scene from the toilet after prolonged opioid use? Ewen MacGregor could have used some Movantik. Movantik is the brand name for the pharmaceutical naloxegol, which is designed to protect the bowels and prevent post-opioid constipation after opiate use. Unlike the movie, most people using Movantik will simply be recovering from post-operative procedures or long-term injuries. Movantik may also help recovering illicit opioid addicts as well since Methadone treatments are mentioned and chemical contraindications of this behavior are not listed unless also comorbid with advanced cancer.

Why Is Movantik Being Studied In Clinical Trials?

Movantik clinical trials are based on the quest to help patients better tolerate opioid pain relief without creating additional health concerns, such as severe constipation. The pill is designed to be a simple oral additive that can be taken by mouth before meals but also may support patients who have NG tubes. Movantik clinical trials are not extensive, but it does not appear that studies have been withdrawn due to side effect concerns or lack of efficacy overall.

How Does Movantik Treatment Work?

Movantik blocks opioids from attaching to a part of your bowel referred to as "mu-receptors". If the opiate cannot reach the mu-receptor, it cannot attach and cause this specific type of constipation. Movantik is not meant for short-term pain or digestive issues and is specifically related to opioid-induced constipation, not other forms of constipation. Side effects follow those associated with many medications including stomach and digestive upset, which may be complicated by opioid withdrawal at the time of consumption.

What Are Some of the Breakthrough Clinical Trials Involving Movantik?

Movantik clinical trials include the currently active trial titled Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer. This trial proposes to use Movantik as prescribed for constipation but also with hopes of lessening or slowing the growth of this cancer. The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured Patients (NIPA) is currently recruiting patients. This study notes the worsened outcomes for mechanically ventilated patients who also suffer from opioid-related constipation. It is proposed that naloxegol may prevent damaging constipation without also adding to the sedation of brain-injured patients. Naloxegol and Opioid-induced Constipation is another study currently recruiting through TriHealth, Inc. to add Movantik to pre-operative cardiac surgery regiments to help prevent post-op opioid constipation.

**Who Are The Key Opinion Leaders On Movantik Clinical Trial Research? **

The National Cancer Institute (NCI) is actively researching naloxegol's uses for both alleviating post-operative complications from constipation and pain management, but also as a potential agent to slow or reduce cancer growth. University Hospital, Brest of France is another leading researcher conducting studies as an organization with their intensive care patients as well. TriHealth supports a large variety of patients and patients' needs at a series of medical facilities in the Cincinnati, Ohio area, and is working to study Movantik for use as a preoperative regimen. Most Movantik clinical trials are facility based, instead of being led by a single researcher or research team.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: November 13th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19;370(25):2387-96. doi: 10.1056/NEJMoa1310246. Epub 2014 Jun 4. https://pubmed.ncbi.nlm.nih.gov/248968182 Anantharamu T, Sharma S, Gupta AK, Dahiya N, Singh Brashier DB, Sharma AK. Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):188-92. doi: 10.4103/0976-500X.162015. https://pubmed.ncbi.nlm.nih.gov/263120113 Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol. 2015 Jul;8(4):206-20. doi: 10.1177/1756283X15578608. Review. https://pubmed.ncbi.nlm.nih.gov/261368384 Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19;370(25):2387-96. doi: 10.1056/NEJMoa1310246. Epub 2014 Jun 4. https://pubmed.ncbi.nlm.nih.gov/248968185 Jones R, Prommer E, Backstedt D. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation. Am J Hosp Palliat Care. 2016 Nov;33(9):875-880. Epub 2015 Jul 6. Review. https://pubmed.ncbi.nlm.nih.gov/261506786 Anantharamu T, Sharma S, Gupta AK, Dahiya N, Singh Brashier DB, Sharma AK. Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):188-92. doi: 10.4103/0976-500X.162015. https://pubmed.ncbi.nlm.nih.gov/263120117 Bowers BL, Crannage AJ. The Evolving Role of Long-Term Pharmacotherapy for Opioid-Induced Constipation in Patients Being Treated for Noncancer Pain. J Pharm Pract. 2019 Oct;32(5):558-567. doi: 10.1177/0897190017745395. Epub 2017 Dec 5. Review. https://pubmed.ncbi.nlm.nih.gov/292079098 DePriest AZ, Miller K. Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence. Pain Ther. 2014 Jun;3(1):1-15. doi: 10.1007/s40122-014-0026-2. Epub 2014 May 6. https://pubmed.ncbi.nlm.nih.gov/25135384